CA3100961A1 - Peptide compounds and therapeutic uses of same - Google Patents

Peptide compounds and therapeutic uses of same Download PDF

Info

Publication number
CA3100961A1
CA3100961A1 CA3100961A CA3100961A CA3100961A1 CA 3100961 A1 CA3100961 A1 CA 3100961A1 CA 3100961 A CA3100961 A CA 3100961A CA 3100961 A CA3100961 A CA 3100961A CA 3100961 A1 CA3100961 A1 CA 3100961A1
Authority
CA
Canada
Prior art keywords
peptide
isolated peptide
proline
amino acid
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3100961A
Other languages
English (en)
French (fr)
Inventor
Eran Ovadia
Avi Ben-Shimon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69141375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3100961(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of CA3100961A1 publication Critical patent/CA3100961A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3100961A 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same Pending CA3100961A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL260555 2018-07-11
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (1)

Publication Number Publication Date
CA3100961A1 true CA3100961A1 (en) 2020-01-16

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3100961A Pending CA3100961A1 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Country Status (20)

Country Link
US (2) US11912790B2 (enExample)
EP (2) EP3820882B1 (enExample)
JP (2) JP7395517B2 (enExample)
KR (1) KR102880543B1 (enExample)
CN (1) CN112351989B (enExample)
AU (2) AU2019300567B2 (enExample)
BR (1) BR112020024748A2 (enExample)
CA (1) CA3100961A1 (enExample)
CO (1) CO2021001290A2 (enExample)
EA (1) EA202190249A1 (enExample)
ES (1) ES3026158T3 (enExample)
HR (1) HRP20250746T1 (enExample)
HU (1) HUE072141T2 (enExample)
IL (2) IL280101B2 (enExample)
MX (1) MX2021000264A (enExample)
PL (1) PL3820882T3 (enExample)
RS (1) RS66946B1 (enExample)
SG (1) SG11202012773QA (enExample)
WO (1) WO2020012478A2 (enExample)
ZA (1) ZA202100587B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280101B2 (en) 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses
IL272074B2 (en) * 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (enExample) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
AU2005276117C1 (en) * 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
KR20070100832A (ko) * 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
US7704953B2 (en) 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
BR112012006005A2 (pt) * 2009-09-17 2017-09-19 Univ Ramot "peptídeos no tratamento de transtorno associados ao estresse oxidativo"
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
PL2655612T3 (pl) * 2010-12-23 2017-12-29 Shell Internationale Research Maatschappij B.V. Czynniki uszkadzające geny produkujące pochodne tłuszczowego acylo-coa
CA2836503C (en) 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
CN104045703B (zh) * 2013-03-15 2021-04-06 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
US8802633B1 (en) 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
EP3169343B1 (en) * 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
US9453061B2 (en) * 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
BR112017022845A2 (pt) 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
IL280101B2 (en) 2018-07-11 2025-05-01 Immunity Pharma Ltd Peptide compounds and their therapeutic uses
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Also Published As

Publication number Publication date
KR102880543B1 (ko) 2025-11-04
EP3820882B1 (en) 2025-04-02
IL280101B1 (en) 2025-01-01
AU2024278477A1 (en) 2025-01-30
RS66946B1 (sr) 2025-07-31
HRP20250746T1 (hr) 2025-08-15
US20210261615A1 (en) 2021-08-26
IL280101A (en) 2021-03-01
ZA202100587B (en) 2022-07-27
AU2019300567A1 (en) 2021-02-25
JP2021531246A (ja) 2021-11-18
CN112351989B (zh) 2024-03-26
EA202190249A1 (ru) 2021-05-21
CO2021001290A2 (es) 2021-02-26
IL317252A (en) 2025-01-01
US20240190919A1 (en) 2024-06-13
US11912790B2 (en) 2024-02-27
PL3820882T3 (pl) 2025-08-11
KR20210045397A (ko) 2021-04-26
WO2020012478A3 (en) 2020-02-20
JP7682248B2 (ja) 2025-05-23
EP3820882C0 (en) 2025-04-02
JP7395517B2 (ja) 2023-12-11
JP2024026217A (ja) 2024-02-28
SG11202012773QA (en) 2021-01-28
CN112351989A (zh) 2021-02-09
MX2021000264A (es) 2021-05-12
EP4566617A3 (en) 2025-10-01
IL280101B2 (en) 2025-05-01
EP4566617A2 (en) 2025-06-11
WO2020012478A2 (en) 2020-01-16
ES3026158T3 (en) 2025-06-10
AU2019300567B2 (en) 2024-09-19
BR112020024748A2 (pt) 2021-03-23
EP3820882A2 (en) 2021-05-19
HUE072141T2 (hu) 2025-10-28

Similar Documents

Publication Publication Date Title
US10040836B2 (en) Peptides for the treatment of neurodegenerative diseases
AU2024278477A1 (en) Peptide compounds and therapeutic uses of same
EP2688582B1 (en) Neuroprotective peptides
CA2773935C (en) Peptides for the treatment of oxidative stress related disorders
RU2762089C2 (ru) ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
AU2015291151B2 (en) Isolated polypeptides of CD44 and uses thereof
CA3167139A1 (en) Peptide compounds and methods of treating diseases using same
RU2843553C2 (ru) Пептидные соединения и их терапевтическое применение
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240917

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241105

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707